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68Ga is a radionuclide of great interest as a positron emitter for PET. To 
develop a new bone-imaging agent with radiogallium,  
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was 
chosen as a chelating site and Ga-DOTA complex-conjugated 
bisphosphonate, which has a high affinity for bone, was prepared and 
evaluated. Although we are interested in developing 68Ga labeled bone 
imaging agents for PET, in these initial studies 67Ga was used because of its 
longer half-life. 
Methods:  
DOTA-conjugated bisphosphonate (DOTA-Bn-SCN-HBP) was synthesized 
by conjugation of 
2-(4-isothiocyanatebenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraac
etic acid (p-SCN-Bn-DOTA) to 
4-amino-1-hydroxybutylidene-1,1-bisphosphonate (alendronate). 
67Ga-DOTA-Bn-SCN-HBP was prepared by coordination with 67Ga, and its 
in vitro and in vivo evaluations were performed. 
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Results:  
67Ga-DOTA-Bn-SCN-HBP was prepared with a radiochemical purity of 
over 95% without purification. 67Ga-DOTA-Bn-SCN-HBP had great affinity 
for hydroxyapatite in binding assay. In biodistribution experiments, 
67Ga-DOTA-Bn-SCN-HBP accumulated in bone rapidly but was hardly 
observed in tissues other than bone. Pretreatment of an excess amount of 
alendronate inhibited the bone accumulation of 67Ga-DOTA-Bn-SCN-HBP. 
Conclusions:  
67Ga-DOTA-Bn-SCN-HBP showed ideal biodistribution characteristics as a 
bone-imaging agent. These findings should provide useful information on 
the drug design of bone-imaging agents for PET with 68Ga. 
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1. Introduction 
Over the last thirty years, complexes of 99mTc with bisphosphonate, 
such as methylene diphosphonate (99mTc-MDP) and hydroxymethylene 
diphosphonate (99mTc-HMDP), have been widely used as 
radiopharmaceuticals for the imaging of bone disorders such as metastatic 
bone disease, Paget’s disease, osteoporotic fractures, etc [1-4]. 
Bisphosphonate analogs have a high affinity for hydroxyapatite and 
accumulate in bone because their phosphonate groups bind to the Ca2+ of 
hydroxyapatite crystals [5]. In the cases of 99mTc-MDP and 99mTc-HMDP, the 
phosphonate groups coordinate with technetium [6], which might decrease 
the inherent accumulation of MDP and HMDP in bone. Thus, we 
hypothesized that the bone affinity of technetium-99m labeled 
bisphosphonate would be increased by the design of a bisphosphonate in 
which the phosphonate groups do not coordinate with technetium-99m. To 
enable imaging at an earlier time after injection, we and other groups have 
designed technetium-99m complex-conjugated bisphosphonate compounds 
based on the concept of bifunctional radiopharmaceuticals [7-10]. As we 
expected, some of the novel technetium-99m complex-conjugated 
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bisphosphonate compounds showed superior biodistribution compared with 
previous compounds. This drug concept is applicable not only to technetium 
complex radiopharmaceuticals but also to other metals, such as rhenium 
[11-18], lutetium [19], yttrium [20], gadolinium [21], and so on. 
68Ga is one of the greatest practical and interesting radionuclides for 
clinical positron emission tomography (PET) because of its radiophysical 
properties (T1/2 = 68 min) [22]. 68Ga is a generator-produced nuclide and can 
be eluted at any time on demand. Specifically, it does not require an on-site 
cyclotron. In principle, the long half-life of the parent nuclide 68Ge (T1/2 = 
270.8 days) provides a long life-span generator. 
In this study, to develop a new tracer with radiogallium for the 
imaging of bone disorders such as bone metastases, 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was 
chosen as a chelating site because it has been well known that Ga forms a 
stable complex with DOTA. Therefore, Ga-DOTA-conjugated 
bisphosphonate was designed, and evaluated by in vitro and in vivo 
experiments. Although we are interested in developing 68Ga labeled bone 
imaging agents for PET, in these initial studies 67Ga was used because of its 
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longer half-life.   
 
2. Materials and methods 
2.1. Materials 
Proton nuclear magnetic resonance (1H-NMR) spectra were recorded 
on a JEOL JNM-ECS600 spectrometer (JEOL Ltd., Tokyo, Japan) and the 
chemical shifts were reported in ppm downfield from an internal 
tetramethylsilane standard. Electrospray ionization mass spectra (ESI-MS) 
were obtained with an LCQ (Thermo Fisher Scientific, Waltham, MA). 67Ga 
was supplied by Nihon Medi-Physics Co., Ltd. (Tokyo, Japan). TLC 
analyses were performed with silica plates (Art 5553, Merck KGaA, 
Darmstadt, Germany). Cellulose acetate electrophoresis (CAE) 
(Separax-SP; Joko Co. Ltd., Tokyo, Japan) was run at an electrostatic field of 
1.0 mA/cm for 20 minutes in veronal buffer (I = 0.06, pH 8.6). 
2-4-Isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraace
tic acid (p-SCN-Bn-DOTA) was purchased from Macrocyclics (Dallas, TX). 
Other reagents were of reagent grade and used as received. 
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2.2. Synthesis of 
4-[3-(4-hydroxy-4,4-bisphosphonobutyl)thioureido]benzyl-1,4,7,10-tetraaz
acyclododecane-1,4,7,10-tetraacetic acid (DOTA-Bn-SCN-HBP (3)) 
(Scheme 1) 
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate (alendronate (2)) 
(2.5 mg, 10 μmol), which was synthesized according to procedures 
described previously [13], was suspended in 150 μL of distilled water and 
then triethylamine (30 μL, 0.2 mmol) was added to the suspension. After a 
few seconds of being stirred at room temperature, the suspension became 
clear. p-SCN-Bn-DOTA (1) (5.5 mg, 10 μmol) was dissolved in 100 μL of 
DMF and then added dropwise to the reaction mixture. After the reaction 
mixture was incubated for 15 hours at 37˚C, the mixture was purified by 
RP-HPLC performed with a Hydrosphere C18 column (10 × 150 mm, YMC, 
Kyoto, Japan) at a flow rate of 4 mL/min with a gradient mobile phase of 
20% methanol in water with 0.1% trifluoroacetic acid to 50% methanol in 
water with 0.1% trifluoroacetic acid for 20 min. Chromatograms were 
obtained by monitoring UV absorption at a wavelength of 254 nm. The 
fraction containing DOTA-Bn-SCN-HBP was determined by mass 
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spectrometry and collected. The solvent was removed by lyophilization to 
provide DOTA-Bn-SCN-HBP (3) (1.6 mg, 20.0%) as a white powder. 
1H NMR (D2O):  1.89-1.99 (m, 4H), 2.90-3.94 (m, 27H), 7.28 (d, 2H), 7.33 
(d, 2H). 
MS (ESI) calcd for C28H46N6O15P2S: (M – H)– m/z 799. Found: 799. 
 
2.3. Preparation of 67Ga-DOTA-Bn-SCN-HBP 
DOTA-Bn-SCN-HBP (3) (50 μg) was dissolved in 75 μL of 0.2 M 
ammonium acetate buffer (pH 5.0) and then 25 μL of 67GaCl3 solution in 
0.01 M HCl was added to the DOTA-Bn-SCN-HBP. The mixture was 
reacted at 95˚C for 30 minutes. 67Ga-DOTA was prepared by the same 
procedure using DOTA instead of DOTA-Bn-SCN-HBP. The radiochemical 
purities were confirmed by CAE and TLC. 
 
2.4. In vitro stability 
To evaluate the stability of 67Ga-DOTA-Bn-SCN-HBP in 
buffered-solution, 67Ga-DOTA-Bn-SCN-HBP (100 μL) was diluted with 0.1 
M phosphate buffer (pH 7.4, 400 μL) and the solution was incubated at 37˚C. 
After 1, 3, 6, and 24 hours of incubation, samples were drawn and 
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radioactivity was analyzed by CAE and TLC. 
To evaluate the stability of 67Ga-DOTA-Bn-SCN-HBP in plasma, 
67Ga-DOTA-Bn-SCN-HBP (50 μL) was diluted 10-fold with freshly 
prepared murine plasma (450 μL), and solutions were incubated at 37˚C for 
24 hours. After 1, 3, 6, and 24 hours incubation, samples (40 μL) were drawn 
and loaded onto Microcon YM-30 filters (MILLIPORE, Billerica, MA) and 
centrifuged at 14000g for 12 minutes at room temperature for separation of 
proteins. Filtrates of radioactivity were analyzed by CAE and TLC. 
 
2.5. Hydroxyapatite-binding assays 
Hydroxyapatite-binding assays were performed according to 
procedures described previously with slight modification [23]. In brief, 
hydroxyapatite beads (Bio-Gel; Bio-Rad, Hercules, CA) were suspended in 
Tris/HCl-buffered saline (50 mM, pH 7.4) at 1 mg/mL, 10 mg/mL, and 25 
mg/mL. For the solutions of 67Ga-labeled compounds 
(67Ga-DOTA-Bn-SCN-HBP and 67Ga-DOTA), the ligand concentrations 
were adjusted to 19.5 µM. Two hundred microliters of each solution of 
67Ga-labeled compound was added to 200 μL of the hydroxyapatite 
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suspension, and the samples were gently shaken for 1 hour at room 
temperature. This period was used because it has been reported that 1 h is 
sufficient to attain binding equilibrium [23]. After centrifugation at 10,000g 
for 5 minutes, the radioactivity of the supernatant was measured with an auto 
well gamma counter (ARC-7010B, Aloka, Tokyo, Japan). Control 
experiments were performed using the same procedure but without the 
hydroxyapatite beads. In the control experiments, we confirmed that the 
radioactivity adsorbed to the vials was less than 0.1%. The rate of binding 
was determined as follows: 
Hydroxyapatite binding (%) = (1 – [radioactivity of supernatant of each 
sample]/[radioactivity of supernatant in the respective control]) × 100 
 
2.6. Biodistribution experiments 
Experiments with animals were conducted in accordance with the 
Guidelines for the Care and Use of Laboratory Animals of Kanazawa 
University. Biodistribution experiments were performed with an intravenous 
administration of each diluted tracer solution (37 kBq / 100 μL) to 
6-week-old male ddY mice (27-32 g, Japan SLC, Inc., Hamamatsu, Japan). 
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To investigate the effect of an excess amount of bisphosphonate on 
biodistribution, alendronate (40 mg/kg) was intravenously administered to 
mice 1 minute before the intravenous injection of 
67Ga-DOTA-Bn-SCN-HBP. Four or five mice each were sacrificed by 
decapitation at 10, 60, and 180 minutes postinjection of the radiotracer. 
Tissues of interest were removed and weighed. The complete left femur was 
isolated as a representative bone sample. The levels of radioactivity in these 
tissues were determined with an auto well gamma counter and corrected for 
background radiation and physical decay during counting. 
 
2.7. Statistical analysis 
Data are expressed as mean ± standard deviation, where appropriate. 
The results were statistically analyzed using unpaired Students’ t test; p = 
0.05 was set as the level of significance. 
 
3. Results 
3.1. Preparation of 67Ga-labeled compounds 
DOTA-Bn-SCN-HBP (3) as a precursor was synthesized by a 
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coupling reaction between p-SCN-Bn-DOTA (1) and alendronate (2) 
according to Scheme 1. 67Ga labeling was performed by complexation 
between DOTA-Bn-SCN-HBP or DOTA and 67Ga. The radiochemical 
purities of 67Ga-DOTA-Bn-SCN-HBP and 67Ga-DOTA were each over 95% 
without purification. 
 
3.2. In vitro stability 
Figure 1 shows the stability of 67Ga-DOTA-Bn-SCN-HBP in 
buffered solution and plasma. After 24 hours of incubation in buffered 
solution, no decomposition of 67Ga-DOTA-Bn-SCN-HBP was observed. 
After 24 hours of incubation in plasma, 80.2 ± 1.0% of 
67Ga-DOTA-Bn-SCN-HBP remained intact. 
 
3.3. Hydroxyapatite-binding assay 
Figure 2 shows the percentages of 67Ga-DOTA-Bn-SCN-HBP and 
67Ga-DOTA as a negative control bound to hydroxyapatite beads. With an 
increase in the amount of hydroxyapatite, the rate of binding of 
67Ga-DOTA-Bn-SCN-HBP rose. In contrast, 67Ga-DOTA did not bind to the 
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hydroxyapatite beads at all. 
 
3.4. Biodistribution experiments 
The biodistributions of 67Ga-DOTA-Bn-SCN-HBP and 67Ga-DOTA 
in normal mice are presented in Tables 1 and 3, respectively. 
67Ga-DOTA-Bn-SCN-HBP showed a high degree of accumulation in bone 
soon after injection, and almost all other radioactivity was quickly excreted 
via the kidneys. Consequently, radioactivity was scarcely observed in any 
tissue without bone at 60 minutes after injection. Meanwhile, 67Ga-DOTA 
did not accumulate in bone, and almost all injected radioactivity was quickly 
excreted via the kidneys.  
The biodistributions of 67Ga-DOTA-Bn-SCN-HBP with pretreatment 
of alendronate (40 mg/kg) in normal mice is presented in Table 2. 
Pretreatment of alendronate inhibited bone accumulation of 
67Ga-DOTA-Bn-SCN-HBP and caused an increase in radioactivity levels in 
most organs except bone, muscle, and brain. 
 
4. Discussion 
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In our previous study, we synthesized a similar ligand, DOTA-HBP, 
which is a DOTA-conjugated bisphosphonate, by coupling the reaction 
between DOTA-NHS-ester and alendronate, and prepared 90Y-DOTA-HBP 
[20]. Because 90Y-DOTA-HBP showed superior biodistribution in mice as a 
bone-seeking radiopharmaceutical, in this study, we first tried to label the 
DOTA-HBP ligand with radiogallium. However, in the case of 67Ga-labeled 
compounds, 67Ga-DOTA-HBP and 67Ga-DOTA were not retained in the 
RP-HPLC column. Thus, the separation of 67Ga-DOTA-HBP and 
67Ga-DOTA as an impurity was impossible. It was reported that four nitrogen 
atoms of the macrocycle and two oxygen atoms from the carboxyl groups are 
involved in the complexation of gallium by DOTA [24]. In contrast, for 90Y, 
it is assumed that four nitrogen atoms and four oxygen atoms from the 
carboxyl groups in DOTA are involved in the complexation. The difference 
of coordination structure might affect retention in the ODS column for 
RP-HPLC. In RP-HPLC analysis after the synthesis reaction of DOTA-HBP, 
the peaks of DOTA-HBP and 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
mono(N-hydroxysuccinimidyl ester) (DOTA-NHS-ester) were close. When 
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we purified DOTA-HBP by RP-HPLC, a subtle amount of DOTA-NHS-ester 
might have mixed with DOTA-HBP. As a result of DOTA-NHS-ester 
hydrolyzation to DOTA, 67Ga-DOTA could mix as an impurity with 
67Ga-DOTA-HBP as a major labeled product. 
In this study, the separation of a precursor with HPLC is easier than 
it was in a previous study because DOTA-Bn-SCN-HBP with a benzene ring 
is more lipophilic compared with DOTA-HBP. Because of the complete 
successful purification of the precursor with HPLC, a high radiochemical 
purity of 67Ga-DOTA-Bn-SCN-HBP was achieved without purification after 
radiolabeling. The lack of a need for purification after radiolabeling could 
facilitate the making of a kit for a radiopharmaceuticals and would be 
beneficial for clinical use. 
Investigations of 68Ga-labeled compounds for bone imaging were 
previously described in the 1970s [25,26]. In these reports, gallium was 
labeled with tripolyphosphate or ethylenediamine tetramethylene 
phosphonate (EDTMP). Since gallium can form a complex with 
tripolyphosphate or EDTMP, there is a possibility that 67Ga coordinates with 
the phosphonate group in DOTA-Bn-SCN-HBP. To ascertain whether 67Ga 
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is selectively complexed with only the DOTA moiety, a mixture containing 
DOTA and alendronate at equal mole concentrations was reacted under the 
same conditions as the labeling reaction of DOTA-Bn-SCN-HBP. Through 
an analysis of this reaction mixture, the 67Ga-labeled product was found to be 
identical to that obtained from the reaction of only DOTA with 67Ga. These 
findings suggest that 67Ga is chelated with the DOTA moiety in 
DOTA-Bn-SCN-HBP. 
In this study, 67Ga-DOTA did not bind HA in vitro and did not 
accumulate in bone in vivo at all (Fig. 2 and Table 3). Moreover, the 
pretreatment of an excess amount of alendronate, which is a bisphosphonate 
compound, greatly reduced the bone accumulation of 
67Ga-DOTA-Bn-SCN-HBP (Table 2). These results indicate that a 
bisphosphonate site in 67Ga-DOTA-Bn-SCN-HBP plays a crucial role for the 
delivery of radiotracer to bone. The effect of the pretreatment of alendronate 
on the pharmacokinetics of 67Ga-DOTA-Bn-SCN-HBP was not limited to 
bone. Actually, the radioactivity of most organs was increased. This could be 
caused by a delay in blood clearance. A previous report stated that there is a 
saturable transport mechanism for alendronate in renal tubular epithelial 
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cells [27]. The delay in blood clearance of 67Ga-DOTA-Bn-SCN-HBP would 
be derived from saturation of the renal transport system by an excess amount 
of alendronate. 
Recently, 68Ga-EDTMP was re-evaluated by Mitterrhauser et al. 
[28]. However, they stated that the advantage of 68Ga-EDTMP over 
[18F]-fluoride was not apparent and that the future clinical prospect of 
68Ga-EDTMP remained speculative. Meanwhile, PET/CT imaging of bone 
metastases with a 68Ga-DOTA complex-conjugated bisphosphonate 
(BPAMD) based on a strategy similar to our study has been reported [29]. 
68Ga-BPAMD showed high uptake in osteoblastic metastases. Surprisingly, 
the maximal standardized uptake was 77.1 and 62.1 in the 10th thoracic and 
L2 vertebra vs. 39.1 and 39.2 for 18F-fluoride PET, respectively. Accordingly, 
we suppose that 67Ga-DOTA-Bn-SCN-HBP also could have a potential for 
the detection of osteoblastic bone metastases such as 68Ga-BPAMD because 
both complexes have similar chemical structures and should have the same 
mechanism of bone adsorption. Actually, 67Ga-DOTA-Bn-SCN-HBP 
showed superior biodistribution in normal mice. The results are comparable 
to those of 99mTc-HMDP (Tables 1 and 4), because it has long been used as a 
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radiopharmaceutical for bone scintigraphy. Furthermore, 
67Ga-DOTA-Bn-SCN-HBP might offer a more ideal structure-based drug 
design as a bone-seeking radiopharmaceutical because 
DOTA-Bn-SCN-HBP has a hydroxyl group (α-OH group) at a central carbon 
of the bisphosphonate structure. On the other hand, BPAMD does not have 
an α-OH group. Previous studies of bisphosphonates suggest that the 
presence of the α-OH group affects affinity for bone minerals [30]. In the 
design of radiometal complex-conjugated bisphosphonate derivatives, it has 
also been suggested that the α-OH group is effective in enhancing 
accumulation in bone [12]. 
In conclusion, a 67Ga DOTA complex-conjugated bisphosphonate 
derivative, 67Ga-DOTA-Bn-SCN-HBP, showed ideal biodistribution 
characteristics as a bone scintigraphy agent. These findings should provide 
useful information on the drug design of PET tracers with 68Ga for diagnosis 
and as a monitor for the therapy of bone disorders, such as bone metastases. 
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Table 1. Biodistribution of radioactivity after intravenous administration of 
67Ga-DOTA-Bn-SCN-HBP in mice. 
 Time after administration 
Tissue 10 min 1 h 3 h 
Blood 1.69 (0.21) 0.13 (0.03) 0.10 (0.02) 
Liver 0.46 (0.04) 0.16 (0.03) 0.19 (0.01) 
Kidney 8.28 (2.66) 3.15 (1.65) 1.05 (0.21) 
Intestine 0.38 (0.05) 0.11 (0.02) 0.11 (0.03) 
Spleen 0.43 (0.04) 0.08 (0.02) 0.11 (0.01) 
Pancreas 0.51 (0.06) 0.10 (0.05) 0.06 (0.01) 
Lung 1.19 (0.17) 0.17 (0.03) 0.12 (0.01) 
Heart 0.60 (0.11) 0.07 (0.03) 0.09 (0.03) 
Stomach 0.23 (0.08) 0.05 (0.03) 0.05 (0.01) 
Femur 17.44 (1.12) 22.28 (2.15) 23.53 (2.34) 
Muscle 0.56 (0.17) 0.16 (0.11) 0.11 (0.04) 
Brain 0.08 (0.05) 0.04 (0.06) 0.01 (0.00) 
F/B ratioa 10.48 (1.88) 189.51 (59.75) 245.96 (70.65)
Data are expressed as % injected dose per gram tissue. Each value represents 
the mean (SD) of five animals. 
a Femur:blood ratio 
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Table 2. Biodistribution of radioactivity after intravenous administration of 
67Ga-DOTA-Bn-SCN-HBP in mice with pretreatment of alendronate (40 
mg/kg). 
 Time after administration 
Tissue 10 min 1 h 3 h 
Blood 2.31 (0.38)* 0.60 (0.14)*** 0.18 (0.04)** 
Liver 2.33 (0.56)*** 1.84 (0.32)*** 1.39 (0.21)***
Kidney 17.68 (1.33)*** 13.81 (1.74)*** 11.91 (1.13)***
Intestine 0.58 (0.12)* 0.36 (0.06)*** 0.29 (0.04)***
Spleen 1.39 (0.17)*** 1.12 (0.42)*** 1.02 (0.40)** 
Pancreas 0.95 (0.09)*** 0.54 (0.04)*** 0.25 (0.08)***
Lung 5.23 (0.58)*** 2.62 (0.69)*** 1.54 (0.42)***
Heart 1.28 (0.32)** 0.47 (0.09)*** 0.28 (0.05)***
Stomach 0.46 (0.11)** 0.61 (0.06)*** 0.74 (0.13)***
Femur 7.51 (1.55)*** 13.71 (1.59)*** 15.16 (1.53)***
Muscle 0.68 (0.09) 0.25 (0.04) 0.15 (0.07) 
Brain 0.06 (0.01) 0.02 (0.01) 0.01 (0.00) 
F/B ratioa 3.36 (0.98)** 23.61 (4.61)*** 85.61 (21.01)*** 
Data are expressed as % injected dose per gram tissue. Each value represents 
the mean (SD) of four animals. 
a Femur:blood ratio 
*p < 0.05 vs. control (no pretreatment) 
**p < 0.01 vs. control (no pretreatment) 
***p < 0.001 vs. control (no pretreatment)
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Table 3. Biodistribution of radioactivity after intravenous administration of 
67Ga-DOTA in mice. 
 Time after administration 
Tissue 10 min 1 h 3 h 
Blood 2.60 (0.32) 0.05 (0.04) 0.00 (0.00) 
Liver 0.58 (0.19) 0.06 (0.02) 0.04 (0.00) 
Kidney 10.81 (4.52) 2.58 (1.74) 0.89 (0.12) 
Intestine 0.51 (0.09) 0.06 (0.01) 0.11 (0.10) 
Spleen 0.59 (0.13) 0.07 (0.02) 0.03 (0.01) 
Pancreas 0.74 (0.15) 0.02 (0.01) 0.01 (0.01) 
Lung 2.02 (0.35) 0.11 (0.04) 0.02 (0.42) 
Heart 0.92 (0.06) 0.06 (0.01) 0.03 (0.01) 
Stomach 0.33 (0.09) 0.03 (0.01) 0.03 (0.03) 
Femur 1.22 (0.37) 0.21 (0.21) 0.07 (0.08) 
Muscle 0.60 (0.16) 0.08 (0.11) 0.03 (0.01) 
Brain 0.07 (0.02) 0.00 (0.00) 0.00 (0.00) 
F/B ratioa 0.47 (0.13) 6.49 (6.96) 9.87 (17.10) 
Data are expressed as % injected dose per gram tissue. Each value represents 
the mean (SD) of four animals. 
a Femur:blood ratio 
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Table 4. Biodistribution of radioactivity after intravenous administration of 
99mTc-HMDP in miceb. 
 Time after administration 
Tissue 10 min 1 h 3 h 
Blood 1.63 (0.23) 0.15 (0.07) 0.07 (0.02) 
Liver 0.48 (0.09) 0.14 (0.04) 0.13 (0.03)* 
Kidney 10.78 (1.66) 5.69 (1.88) 0.85 (0.35) 
Intestine 0.41 (0.05) 0.12 (0.02) 0.17 (0.04)* 
Spleen 0.46 (0.08) 0.11 (0.03) 0.07 (0.02)* 
Stomach 0.29 (0.08) 0.21 (0.20) 0.26 (0.28) 
Femur 16.89 (2.12) 19.65 (1.76) 19.21 (2.08)* 
Muscle 0.61 (0.15) 0.15 (0.06) 0.17 (0.12) 
F/B ratioa 10.44 (1.49) 149.42 (67.11) 291.06 (61.64)
Data are expressed as % injected dose per gram tissue. Each value represents 
the mean (SD) of five animals. 
a Femur:blood ratio 
b Previously reported results [20] 
*p < 0.05 vs. 67Ga-DOTA-Bn-SCN-HBP 
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Figure Legends 
Scheme 1. Synthesis of DOTA-Bn-SCN-HBP.  
Figure 1. Stability of 67Ga-DOTA-Bn-SCN-HBP in buffered solution 
(closed circles) and in plasma (open circles). Data are expressed as the mean 
± SD for three experiments. 
Figure 2. Each column represents the binding of 67Ga-DOTA (closed 
column) and 67Ga-DOTA-Bn-SCN-HBP (open column) to hydroxyapatite 
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